Multispectral Optoacoustic Tomography (MSOT) is a cutting-edge imaging technique that holds great promise for clinical cancer imaging applications. By leveraging the photoacoustic effect, MSOT enables the generation of high-resolution medical images with excellent contrast at depths of up to 5 cm. The system has shown significant success in preclinical studies and is now transitioning into clinical settings, particularly for cancers such as breast, prostate, gynecologic, and dermatologic malignancies. MSOT allows for multiwavelength illumination, enabling the mapping of various chromophores, both endogenous and exogenous, within tissue. However, the translation of MSOT to clinical practice is still in its early stages, requiring further refinement of probes and data acquisition systems to suit human anatomy and real-time visualization settings.
Optoacoustic imaging, including MSOT, is gaining popularity due to its high spatial and spectral resolution coupled with remarkable tissue penetration capabilities. By utilizing near-infrared light, optoacoustic imaging minimizes photon scatter within tissues, allowing for deeper imaging without compromising resolution. Optoacoustic techniques span from macroscopic applications like optoacoustic CT to microscopic imaging with optoacoustic microscopy. While the latter offers superior resolution, it is limited in depth penetration. Optoacoustic tomography, capable of imaging up to 5 cm deep, provides a noninvasive method for organ imaging in a clinical environment, often in conjunction with ultrasound imaging to offer comprehensive tissue visualization.
In the clinical setting, MSOT systems typically consist of lasers for tissue illumination, transducers for signal detection, and sophisticated data acquisition and processing systems. The use of multiple wavelengths in MSOT permits the identification of different chromophores based on their unique spectral properties. Spectral unmixing algorithms play a crucial role in identifying and separating these chromophores, providing detailed information for disease detection and monitoring. Both endogenous and exogenous contrast agents are employed to enhance imaging contrast, with endogenous agents like hemoglobin offering innate contrast while exogenous agents like organic dyes and nanoparticles are tailored for specific molecular targeting. The development of optoacoustic imaging probes for different cancers, such as breast, prostate, and gynecologic malignancies, has shown promising results in differentiating between benign and malignant lesions, aiding in treatment planning and monitoring.
The potential of MSOT in clinical oncology lies in its ability to provide real-time, noninvasive imaging with molecular, functional, and anatomic details. By combining the strengths of optoacoustic imaging with other modalities like ultrasound or fluorescence imaging, MSOT offers a comprehensive approach to cancer diagnosis and treatment. The use of contrast agents, both endogenous and exogenous, further enhances the specificity and sensitivity of cancer detection, paving the way for personalized and precise oncology care. As advancements continue in probe design, imaging algorithms, and contrast agent development, the clinical translation of MSOT holds great promise in revolutionizing cancer imaging and therapy monitoring.
Key Takeaways:
– Multispectral Optoacoustic Tomography (MSOT) shows immense potential for clinical cancer imaging applications.
– Optoacoustic imaging combines high-resolution, deep-tissue penetration with molecular and functional information.
– Integration of multiple wavelengths and contrast agents enhances the specificity and sensitivity of cancer detection.
– Continued advancements in probe design and imaging algorithms are driving the clinical translation of MSOT for oncology applications.
Read more on pmc.ncbi.nlm.nih.gov